These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 37698679)
21. Identification of immunogenic cell death-related subtypes used for predicting survival and immunotherapy of endometrial carcinoma through a bioinformatics analysis. Liu Z; Luo Y; Su L; Hu X Medicine (Baltimore); 2023 Aug; 102(31):e34571. PubMed ID: 37543760 [TBL] [Abstract][Full Text] [Related]
22. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma. Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K Front Immunol; 2023; 14():1202324. PubMed ID: 37457742 [TBL] [Abstract][Full Text] [Related]
23. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R Front Immunol; 2022; 13():990790. PubMed ID: 36248822 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma. Cao L; Liu M; Ma X; Rong P; Zhang J; Wang W Curr Med Chem; 2024; 31(17):2414-2430. PubMed ID: 37936457 [TBL] [Abstract][Full Text] [Related]
25. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas. Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y Front Immunol; 2023; 14():1102094. PubMed ID: 37153540 [TBL] [Abstract][Full Text] [Related]
26. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response. Chen J; Chen X; Li T; Wang L; Lin G Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273 [TBL] [Abstract][Full Text] [Related]
27. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features. Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090 [TBL] [Abstract][Full Text] [Related]
28. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma. Wang S; Gao S; Shan L; Qian X; Luan J; Lv X PeerJ; 2023; 11():e14691. PubMed ID: 36650832 [TBL] [Abstract][Full Text] [Related]
29. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma. Yang L; Zhang W; Yan Y Aging (Albany NY); 2023 Jul; 15(13):6135-6151. PubMed ID: 37399661 [TBL] [Abstract][Full Text] [Related]
31. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma. Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma. Chen W; Shu K; Cai C; Ding J; Zhang X; Zhang W; Wang K Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37584192 [TBL] [Abstract][Full Text] [Related]
33. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595 [TBL] [Abstract][Full Text] [Related]
34. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma. Zhou S; Lu Y; Chen Y; Gan W Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W Front Immunol; 2022; 13():843408. PubMed ID: 35693827 [TBL] [Abstract][Full Text] [Related]
36. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma. Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J Front Immunol; 2022; 13():994259. PubMed ID: 36341373 [TBL] [Abstract][Full Text] [Related]
37. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
38. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma. Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346 [TBL] [Abstract][Full Text] [Related]
39. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma. Xiao Y; Li J; Wu J BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171 [TBL] [Abstract][Full Text] [Related]
40. An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma. Wu X; Jin B; Liu X; Mao Y; Wan X; Du S J Cancer Res Clin Oncol; 2023 Sep; 149(12):10319-10333. PubMed ID: 37273105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]